

# Koichi Takahashi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6237181/publications.pdf>

Version: 2024-02-01

101  
papers

5,231  
citations

109264

35  
h-index

95218

68  
g-index

111  
all docs

111  
docs citations

111  
times ranked

6022  
citing authors

#	ARTICLE	IF	CITATIONS
1	Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. <i>Leukemia</i> , 2022, 36, 257-262.	3.3	19
2	Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. <i>Blood</i> , 2022, 139, 907-921.	0.6	34
3	Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. <i>Bone Marrow Transplantation</i> , 2022, 57, 370-376.	1.3	8
4	Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. <i>Blood Cancer Journal</i> , 2022, 12, 10.	2.8	48
5	Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). <i>Blood Cancer Journal</i> , 2022, 12, 5.	2.8	49
6	Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. <i>Leukemia</i> , 2022, 36, 1253-1260.	3.3	9
7	Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. <i>Leukemia</i> , 2022, 36, 1343-1350.	3.3	23
8	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. <i>Nature Medicine</i> , 2022, 28, 557-567.	15.2	26
9	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2161-2170.	0.6	12
10	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. <i>Lancet Haematology</i> , 2022, 9, e350-e360.	2.2	26
11	Hypomethylating agent and venetoclax with FLT3 inhibitor "triple" therapy in older/unfit patients with FLT3 mutated AML. <i>Blood Cancer Journal</i> , 2022, 12, 77.	2.8	33
12	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	2.6	29
13	Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, 1035-1043.	2.0	31
14	Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. <i>Nature Communications</i> , 2022, 13, 2801.	5.8	25
15	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3848-3857.	0.8	41
16	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. <i>Blood Cancer Discovery</i> , 2021, 2, 125-134.	2.6	50
17	Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 192, 1054-1063.	1.2	28
18	Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021, 11, 25.	2.8	85

#	ARTICLE	IF	CITATIONS
19	Decitabine and venetoclax for <i>IDH1/2</i> -mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E154-E157.	2.0	19
20	Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	56
21	Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. <i>Blood Advances</i> , 2021, 5, 2173-2183.	2.5	35
22	Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. <i>Cancer</i> , 2021, 127, 2641-2647.	2.0	15
23	Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. <i>Blood Cancer Journal</i> , 2021, 11, 98.	2.8	24
24	Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 2607.	5.8	61
25	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. <i>Leukemia</i> , 2021, 35, 3421-3429.	3.3	22
26	Nuclear NAD <sup>+</sup> homeostasis governed by NMNAT1 prevents apoptosis of acute myeloid leukemia stem cells. <i>Science Advances</i> , 2021, 7, .	4.7	18
27	Outcomes of <i>TP53</i> -mutant acute myeloid leukemia with decitabine and venetoclax. <i>Cancer</i> , 2021, 127, 3772-3781.	2.0	80
28	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2021, 39, 2768-2778.	0.8	173
29	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. <i>Nature Communications</i> , 2021, 12, 6071.	5.8	44
30	Preclinically Effective Menin Inhibitor SNDX-50469 and SNDX-5613-Based Combinations Against MLL1-Rearranged (MLL-r) or NPM1-Mutant AML Models. <i>Blood</i> , 2021, 138, 3340-3340.	0.6	3
31	Untangling the Relationship Between Clonal Hematopoiesis and Ovarian Cancer Therapies. <i>Journal of the National Cancer Institute</i> , 2021, , .	3.0	0
32	Statistical tests for intra-tumour clonal co-occurrence and exclusivity. <i>PLoS Computational Biology</i> , 2021, 17, e1009036.	1.5	6
33	Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. <i>Nature Communications</i> , 2020, 11, 5327.	5.8	208
34	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology</i> , the, 2020, 7, e724-e736.	2.2	201
35	Fidelity of peripheral blood for monitoring genomics and tumor immune microenvironment in myelodysplastic syndromes. <i>EJHaem</i> , 2020, 1, 552-557.	0.4	3
36	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. <i>Lancet Haematology</i> , the, 2020, 7, e523-e533.	2.2	43

#	ARTICLE	IF	CITATIONS
37	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , 2020, 52, 1219-1226.	9.4	367
38	Prognostic and therapeutic impacts of mutant <i>TP53</i> variant allelic frequency in newly diagnosed acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 5681-5689.	2.5	105
39	Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. <i>Leukemia</i> , 2020, 34, 2914-2924.	3.3	7
40	T(6;14)(q25;q32) involves BCL11B and is highly associated with mixed-phenotype acute leukemia, T/myeloid. <i>Leukemia</i> , 2020, 34, 2509-2512.	3.3	14
41	Mechanistic basis and efficacy of targeting the $\beta$ -catenin/TCF7L2/JMJD6/c-Myc axis to overcome resistance to BET inhibitors. <i>Blood</i> , 2020, 135, 1255-1269.	0.6	27
42	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. <i>Blood Advances</i> , 2020, 4, 1311-1320.	2.5	106
43	Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial. <i>Blood</i> , 2020, 136, 53-55.	0.6	8
44	Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 22-25.	0.6	2
45	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. <i>Blood</i> , 2020, 136, 42-43.	0.6	11
46	Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 20-22.	0.6	8
47	Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020, 136, 17-19.	0.6	10
48	Outcomes with Sequential FLT3-Inhibitor (FLT3i) Based Therapies in Patients (pts) with FLT3-Mutated Acute Myeloid Leukemia (AML) Exposed to Prior FLT3i Based Therapies. <i>Blood</i> , 2020, 136, 22-24.	0.6	2
49	Single-Cell Characterization of Acute Myeloid Leukemia (AML) and Its Microenvironment Identifies Signatures of Resistance to PD-1 Blockade Based Therapy. <i>Blood</i> , 2020, 136, 29-31.	0.6	0
50	Clonal Expansion of Mutant p53 Clones By MDM2 Inhibition in Acute Myeloid Leukemias. <i>Blood</i> , 2020, 136, 27-28.	0.6	2
51	Baseline Mutations Lack Impact on Clinical Outcomes and Molecular Response in Core Binding Factor Leukemia Treated with Highly Effective Regimen. <i>Blood</i> , 2020, 136, 36-37.	0.6	0
52	Immunologic Predictors for Clinical Responses in Patients with Myelodysplastic Syndromes Treated with Immune Checkpoint Blockade. <i>Blood</i> , 2020, 136, 4-4.	0.6	0
53	Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib. <i>Blood</i> , 2020, 136, 40-41.	0.6	2
54	Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens. <i>Blood</i> , 2020, 136, 41-43.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Outcomes of <i>De Novo</i> Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine. <i>Blood</i> , 2020, 136, 11-13.	0.6	3
56	Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 45-47.	0.6	0
57	Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. <i>Blood</i> , 2020, 136, 43-45.	0.6	10
58	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. <i>Blood Advances</i> , 2019, 3, 508-518.	2.5	62
59	The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. <i>British Journal of Haematology</i> , 2019, 187, e1-e4.	1.2	4
60	PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemiaâ€“initiating cells. <i>Blood</i> , 2019, 134, 614-625.	0.6	16
61	Ibrutinib and Venetoclax for First-Line Treatment of CLL. <i>New England Journal of Medicine</i> , 2019, 380, 2095-2103.	13.9	388
62	RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. <i>Blood</i> , 2019, 134, 59-73.	0.6	75
63	Hematologic malignancies and Liâ€“Fraumeni syndrome. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003210.	0.5	45
64	Germline polymorphisms and the risk of therapy-related myeloid neoplasms. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 24-30.	0.7	5
65	NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. <i>Blood Advances</i> , 2019, 3, 922-933.	2.5	84
66	Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. <i>Blood Advances</i> , 2019, 3, 1533-1539.	2.5	9
67	Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 142-148.e1.	0.2	39
68	TP73 As Novel Determinant of Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1251-1251.	0.6	1
69	Ups and downs of CHIP. <i>Blood</i> , 2018, 131, 1773-1774.	0.6	0
70	Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , 2018, 131, 1820-1832.	0.6	40
71	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1788-1797.	0.8	156
72	PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. <i>Cell Stem Cell</i> , 2018, 23, 700-713.e6.	5.2	272

#	ARTICLE	IF	CITATIONS
73	A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. <i>Blood</i> , 2018, 132, 1664-1674.	0.6	62
74	AML: Predicting the Unpredictable. <i>Cell Stem Cell</i> , 2018, 23, 162-163.	5.2	1
75	Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. <i>Nature Communications</i> , 2018, 9, 2670.	5.8	79
76	High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics. <i>Genome Research</i> , 2018, 28, 1345-1352.	2.4	175
77	Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. <i>Nature</i> , 2017, 542, 362-366.	13.7	105
78	Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. <i>Lancet Oncology</i> , The, 2017, 18, 100-111.	5.1	296
79	Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. <i>Cancer</i> , 2017, 123, 3050-3060.	2.0	47
80	Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 897-901.	0.2	127
81	Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. <i>Blood Advances</i> , 2017, 1, 1312-1323.	2.5	83
82	Copy number alterations detected as clonal hematopoiesis of indeterminate potential. <i>Blood Advances</i> , 2017, 1, 1031-1036.	2.5	30
83	Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. <i>American Journal of Hematology</i> , 2016, 91, E274-6.	2.0	2
84	<i>TP53</i> mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. <i>Cancer</i> , 2016, 122, 3484-3491.	2.0	200
85	Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 163-168.e2.	0.2	18
86	Clinical implications of <i>TP53</i> mutations in myelodysplastic syndromes treated with hypomethylating agents. <i>Oncotarget</i> , 2016, 7, 14172-14187.	0.8	86
87	Characteristics, clinical outcome, and prognostic significance of <i>IDH</i> mutations in <i>AML</i> . <i>American Journal of Hematology</i> , 2015, 90, 732-736.	2.0	242
88	Detectable <i>FLT3</i> -ITD or <i>RAS</i> mutation at the time of transformation from MDS to AML predicts for very poor outcomes. <i>Leukemia Research</i> , 2015, 39, 1367-1374.	0.4	48
89	<i>JAK2</i> p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. <i>Blood</i> , 2013, 122, 3784-3786.	0.6	29
90	Chromosome 5q deletion is extremely rare in patients with myelofibrosis. <i>Leukemia Research</i> , 2013, 37, 552-555.	0.4	9

#	ARTICLE	IF	CITATIONS
91	Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD. British Journal of Haematology, 2013, 161, 659-666.	1.2	20
92	Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood, 2013, 122, 2807-2811.	0.6	50
93	Characteristics and Outcomes Of Patients (pts) With Multiple Myeloma (MM) Who Develop Therapy (t)-Related Myelodysplastic Syndrome (MDS), t-Chronic Myelomonocytic Leukemia (CMML), Or t-Acute Myeloid Leukemia (AML). Blood, 2013, 122, 1424-1424.	0.6	0
94	A Phase II Expansion Study Of Vorinostat In Combination With Idarubicin and Cytarabine For Patients With Acute Myelogenous Leukemia (AML) With FLT3 Molecular Alterations. Blood, 2013, 122, 2684-2684.	0.6	2
95	Fludarabine and Cytarabine Based Induction Therapy Is Associated With High Response Rate and Durable Remission With Low Treatment Related Mortality In Elderly Patients With Core-Binding Factor AML (CBF-AML). Blood, 2013, 122, 3945-3945.	0.6	0
96	Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection. Leukemia Research, 2012, 36, 1376-1379.	0.4	13
97	Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML). Blood, 2012, 120, 3797-3797.	0.6	0
98	Serum CCL3 and CCL4 Levels Function As Novel Prognostic Markers in Diffuse Large B Cell Lymphoma.. Blood, 2012, 120, 2709-2709.	0.6	0
99	Incidence and Prognostic Impact of Cytogenetic and Molecular Clonal Evolution in Relapsed and Refractory Acute Myeloid Leukemia (AML) Patients: Study of Sequential Cytogenetic and Molecular Mutational Analysis.. Blood, 2012, 120, 2562-2562.	0.6	4
100	Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis. Blood, 2012, 120, 3802-3802.	0.6	0
101	Distinct Clinical Characteristics of Myelodysplastic Syndrome in Human Immunodeficiency Virus-Infected Patients.. Blood, 2011, 118, 3821-3821.	0.6	0